Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
An In-depth Analysis of Amobarbital's R&D Progress and Mechanism of Action on Drug Target
20 September 2023
This article summarized the latest R&D progress of Amobarbital, the Mechanism of Action for Amobarbital, and the drug target R&D trends for Amobarbital.
Latest Hotspot
3 min read
RS Oncology Reports New Preclinical Evidence Show RSO-021 Could Halt and/or Revert the Advancement of Severe Mesotheliomas
20 September 2023
At the 2023 IASLC World Lung Cancer Conference in Singapore, RS Oncology shared a first-of-its-kind PRX3 inhibitor, RSO-021's potential to combat swift mesothelioma tumor progression.
Drug Insights
4 min read
Salicylamide: Detailed Review of its Transformative R&D Success
20 September 2023
This article summarized the latest R&D progress of Salicylamide, the Mechanism of Action for Salicylamide, and the drug target R&D trends for Salicylamide.
Valuable Targets
4 min read
Progress in the Research of COMT Inhibitors
20 September 2023
Catechol O-methyltransferase (COMT) is an enzyme responsible for the O-methylation of endogenous neurotransmitters, xenobiotics, and hormones with catechol structures.
Drug Insights
4 min read
Decoding Vilobelimab: A Comprehensive Study of its R&D Trends
19 September 2023
This article summarized the latest R&D progress of Vilobelimab, the Mechanism of Action for Vilobelimab, and the drug target R&D trends for Vilobelimab.
Latest Hotspot
3 min read
InnoCare Reveals approval of the Clinical Experiment for ICP-189, Coupled with EGFR Inhibitor Furmonertinib
19 September 2023
InnoCare Pharma announced that it received IND approval for a Chinese clinical trial to study the effects of new SHP2 allosteric inhibitor, ICP-189.
Drug Insights
4 min read
Deep Scientific Insights on Vandetanib's R&D Progress
19 September 2023
This article summarized the latest R&D progress of Vandetanib, the Mechanism of Action for Vandetanib, and the drug target R&D trends for Vandetanib.
Bio Sequence
2 min read
Strategy for Retrieving Bispecific Antibody Sequences
19 September 2023
Using the Patsnap Bio Sequence Database for bispecific antibody sequence retrieval is recommended.
Drug Insights
4 min read
An In-depth Analysis of Thioguanine's R&D Progress and Mechanism of Action on Drug Target
19 September 2023
This article summarized the latest R&D progress of Thioguanine, the Mechanism of Action for Thioguanine, and the drug target R&D trends for Thioguanine.
Latest Hotspot
3 min read
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
19 September 2023
Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.
Drug Insights
4 min read
Stavudine: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Stavudine, the Mechanism of Action for Stavudine, and the drug target R&D trends for Stavudine.
Advanced Tech.
10 min read
"Super drugs" for treating cancer and AIDS: Chemokines family
19 September 2023
Chemokines, also known as chemotactic cytokines, are a group of factors that, in conjunction with their cell surface receptors, induce the directed migration of leukocytes.